Nearly 40 new medicines to be reimbursed to patients from early 2023
Every year, dozens of new medicines are added to the lists of reimbursable medicines, helping to ensure that Lithuanian patients receive effective and modern treatment. The faster inclusion of new medicines in the reimbursement system is made possible by significantly faster evaluation of new medicines and more rational use of the Compulsory Health Insurance Fund (CHIF).
"The list of reimbursable medicines is continuously updated to ensure that new medicines with additional therapeutic benefits for the health of patients become available to the Lithuanian population as soon as possible. Last year, the number of recommendations made on applications to include new medicinal products in the lists of reimbursable medicines more than doubled, thanks to the strengthening of the capacity to assess health technologies related to medicinal products. The new pricing mechanism for medicines helps to rationalise the use of the PSDF budget and to use the money saved to reimburse new medicines or to widen the range of patients eligible for reimbursement," says Aurimas Pečkauskas, Deputy Minister of Health.
In 2023, 22 medicines were added to the list of reimbursable medicines for depression, multiple sclerosis, hereditary angioedema, breast, lung, liver and blood cancer, rheumatoid arthritis, atopic dermatitis, narcolepsy, infertility and spinal muscular atrophy.
This year, 19 new medicines have already been launched for patients to treat ankylosing spondylitis, heart failure, ovarian, fallopian tube and peritoneal, prostate, lung, blood, breast, head and neck cancers, chronic fibrotic lung and kidney diseases, human immunodeficiency virus (HIV) infection, chronic viral hepatitis C infection.
In addition, the Commission for Medicinal Products and Medical Devices, at its meeting on 6 June 2024, adopted a decision on the transfer of medicinal products included in the Reserve List of Medicinal Products to the List of Diseases and Reimbursable Medicinal Products to Treat Them (List A). The Commission decided to propose to the Minister to reimburse 4 medicinal products for the treatment of cystic fibrosis, acute myeloid leukaemia, prostate cancer and locally advanced or metastatic urothelial carcinoma as from 1 August. Medicines will only start to be reimbursed once applicants have signed treatment access and risk-sharing agreements with the State Patients' Fund.
The State Medicines Control Agency has evaluated 25 applications for inclusion of medicines in the lists of reimbursable medicines in 2022. With a larger team of assessors mobilised for this process, the number of applications assessed in 2023 has increased to 65.
1.24 million people use reimbursed medicines. Around 40% of the Lithuanian population is reimbursed for the full cost of the medicine - primarily for the most vulnerable patient groups, who bear a high financial burden when purchasing reimbursed medicines. There is also a "patient premium basket" as a means of reducing the cost of medicines, which ensures that the amount of premiums per patient per year does not exceed the average of three annual premiums for reimbursed medicines with the lowest premium, based on the previous calendar year. This year, this amount is €48.33.
The measures implemented to reduce patients' premiums are effective, as shown by the reduction in patients' costs. In 2017, the average premium for a reimbursable prescription was €5 and in 2023 it will be €3.17. In total, patients spent €54.2 million on premiums in 2017 and €19.8 million in 2023. This means that patients have saved €34 million over five years.
The PSDF budget's expenditure on reimbursement of medicines and PPPs almost doubled between 2018 and 2023, from €250 million to €491 million. This year, the PSDF budget foresees €509 million for the reimbursement of medicines and PPPs.
Last updated: 15-07-2024
Related news:
Minister for Health A. Pečkauskas attends the Health Systems Sustainability Conference in Brussels
Minister of Health A. Pečkauskas attends child nutrition event in Kyiv
Technical cooperation agreement on health signed with Ukraine
Ministry of Health launches social campaign "Bribery is a bad habit"